TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03614000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening Questionnaires
Description: Measurement tools:~* Social Responsiveness Scale (SRS-2) is a validated 65-item scale for the screening of ASD that requires parents to rate the child's behaviors in the previous 6 months. The questionnaire assesses interpersonal behavior, communication and repetitive/stereotypic behavior characteristics of ASD.~* The Aseba Questionnaires are validated diagnostic tools that can be filled in by the parents, teachers or children to evaluate various behavioral and emotional problems. The CBCL assesses internalizing (i.e., anxious, depressive and over-controlled) and externalizing (i.e., aggressive, hyperactive, noncompliant and under-controlled) behaviors.~* The VG\&O The VG\&O is a questionnaire developed in Dutch that gives a subscale of parental stress (OBVL), family functioning (VGFO), education habits (VSOG) and life events (VMG). The OBVL will be used
Study: NCT02905162

Intervention type: OTHER
Intervention: Transitional HIV care for prison releasees
Description: Transitional HIV care program for releasees
Study: NCT04222491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Description: Peanut oral immunotherapy for peanut allergy
Study: NCT01235988

Intervention type: DRUG
Intervention: Eltrombopag
Description: Eltrombopag 50mg \& standard of care

Intervention type: DRUG
Intervention: Placebo
Description: Placebo + standard of care
Study: NCT02017002

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ivor Lewis
Description: for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tri-incision
Description: a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
Study: NCT01517217

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No girdle
Description: No girdle is used for the first five postoperative days

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Girdle
Description: Girdle the first five postoperative days
Study: NCT04443335

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: continous feeding
Description: At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. Patients in the CF group received continuous feeding with constant velocity by enteral feeding pump over one day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sequential feeding
Description: At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. In the SF group, continuous feeding was changed into time-restricted feeding. The total daily dosage of enteral nutrition was equally distributed during three time periods at 7-9:00, 11-13:00 and 17-19:00. Other times of the day were fasting times. Enteral nutritional suspension in each time period was administered at a uniform rate within two hours by an enteral feeding pump.
Study: NCT01893606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-D-glucosamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00975416

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Intranasal oxytocin given in the context of cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Intranasal oxytocin given in the context of cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Intranasal oxytocin given in the context of cognitive behavioral therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxytocin
Description: Intranasal oxytocin given in the context of cognitive behavioral therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxytocin
Description: Intranasal oxytocin given in the context of cognitive behavioral therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxytocin
Description: Intranasal oxytocin given in the context of cognitive behavioral therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given in the context of cognitive behavioral therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given in the context of cognitive behavioral therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given in the context of cognitive behavioral therapy
Study: NCT00235807

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tinnitus Masking
Description: Sound therapy with Tinnitus Masking is intended to produce immediate relief from the discomfort caused by tinnitus (Vernon, 1977; 1987; Vernon, 1988). If maskers or combination units are used, the masking sound can be set at any level the patient chooses to attain maximum relief. Relief using masking noise can be accomplished using the external sound of the masker, which is generally a more acceptable sound than the tinnitus.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tinnitus Retraining Therapy (TRT)
Description: The TRT procedure adheres as closely as possible to the methodology described by Dr. Pawel Jastreboff. For TRT, sound therapy is used to facilitate long-term habituation to tinnitus (Jastreboff, 1999b).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tinnitus Education (TED)
Description: TED represents tinnitus treatment that would typically be provided by audiologists using hearing aids and counseling (although for this study the counseling has been structured and expanded to be equivalent in length to the other two groups).
Study: NCT00697320

Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: A NON INTERVENTIONAL OBSERVATIONAL STUDY:~Doses and frequency of injections to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT02507076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isolated limb perfusion
Description: Undergo ILP with melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Undergo ILP with melphalan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02365883

Intervention type: DEVICE
Intervention: Photoacoustic Imaging System
Description: manufactured by Endra
Study: NCT01997125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural Bridge System
Description: Implanted device
Study: NCT00937534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan 240mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan 240mg/day
Study: NCT02143817

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline supplementation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training
Description: The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 8 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training
Description: The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 8 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
Study: NCT00914121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study: NCT00848016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-gossypol acetic acid
Description: Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Study: NCT02222662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent massage tx group
Description: The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent massage wait-list control group
Description: The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
Study: NCT01014234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporins
Description: These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
Study: NCT03738735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: For the intervention group, the surgical staff will add 120 mL of 23.4% saline to the 3L bags of lactated Ringer's solution, and this new solution will be used for arthroscopic irrigation purposes throughout the rotator cuff repair surgery.
Study: NCT01381120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate treatment
Description: Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone and acetaminophen combination treatment
Description: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone and acetaminophen combination treatment
Description: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
Study: NCT02944292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deepening of sedation
Description: Deepening of sedation will be achieved with a bolus and subsequent continuous infusion of propofol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be dosed according to lean body weight (LBW) for bolus administration and according to total body weight (TBW) for continuous infusion.~All patients will receive a bolus of propofol 1 mg/kg LBW as a rapid infusion during one minute. Measurements will be made one minute after the ending of bolus infusion. Continuous infusion of propofol at a rate of 3 mg/kg/h will be started immediately following completion of measurements, not later than 5 minutes after bolus administration. The propofol infusion rate is decreased in case of hemodynamic instability by 1 mg/kg/h and until a minimum of 1 mg/kg/h, if needed. Maximum total dose of infusion of 5 mg/kg/h will not be exceeded (bolus not considered).
Study: NCT00743210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: Oral L-citrulline, 3 grams once per day for 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 3 grams once per day for 3 weeks.
Study: NCT03242785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-monitoring/Self-titration
Description: The intervention of the ADAMPA trial is not pharmacological but an intervention that modifies usual clinical practice. The intervention of self-monitoring and self-titration of the medication is composed of 3 elements:~1. Education of the patient: information and training on hypertension, its risks, management, the benefits of an adequate control and the generic measures for an optimal control.~2. Training for self-monitoring: Patients will be trained to perform the self-measurement of blood pressure correctly (and recording their values in the sheet enabled for this purpose)~3. Training for self-titration: patients will be instructed on the target BP numbers, individualized for each patient, on the mode of action against specific figures, including self-adjustment of drug treatment.
Study: NCT04172740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse (calcium hydroxylpatite)
Description: RADIESSE® injectable implant is a sterile, non-pyrogenic, semi-solid, cohesive implant, whose principle component is synthetic calcium hydroxylapatite (CaHA) suspended in a gel carrier of sterile water for injection, glycerin and sodium carboxymethylcellulose. RADIESSE injectable implant has a CaHA particle size range of 25-45 microns. RADIESSE is available in 1.5cc and 0.8cc pre-filled syringes.~RADIESSE injectable implant is indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and it is also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy).
Study: NCT01723072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Humanized monoclonal antibody against human IgE

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to omalizumab
Study: NCT00689065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CALAA-01
Description: Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
Study: NCT00635505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol HFA (Armstrong's)
Description: 180 mcg QID 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol HFA (Proventil HFA)
Description: 180 mcg QID 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HFA placebo
Description: 2 actuations QID 12 weeks or until use of rescue drug
Study: NCT01562899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: Supplied as sterile liquid for intravenous infusion in vials in boxes. Until April 2013 a frozen formulation with a concentration of 30 mg/ml was used; from May 2013 onwards a refrigerated formulation with a concentration of 70 mg/ml was used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: Supplied as sterile liquid for intravenous infusion in vials in boxes. Until April 2013 a frozen formulation with a concentration of 30 mg/ml was used; from May 2013 onwards a refrigerated formulation with a concentration of 70 mg/ml was used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: Supplied as sterile liquid for intravenous infusion in vials in boxes. Until April 2013 a frozen formulation with a concentration of 30 mg/ml was used; from May 2013 onwards a refrigerated formulation with a concentration of 70 mg/ml was used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: Supplied as sterile liquid for intravenous infusion in vials in boxes. Until April 2013 a frozen formulation with a concentration of 30 mg/ml was used; from May 2013 onwards a refrigerated formulation with a concentration of 70 mg/ml was used.
Study: NCT00880126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Development Teams
Description: CDTs bring together counties who are implementing a new practice
Study: NCT04271215

Intervention type: OTHER
Intervention: Chemotherapy protocol used
Description: Chemotherapy protocol used in each participating hospital
Study: NCT00855348

Intervention type: OTHER
Intervention: All eligible subjects will provide blood for SEPT9 biomarker testing
Description: A single blood sample per participant selected according to analysis plan is tested for evidence of methylation of a specific DNA sequence, SEPT9.
Study: NCT03337126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Tablet
Description: Comparator Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Tablet
Description: Comparator Drug
Study: NCT03363906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide (Reference)
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide (Test)
Description: Administered SC
Study: NCT05531877

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Penile Prosthesis Implantation
Description: Penile measurement are taken preoperatively to serve as a guide to the surgeon to optimize post-operative penile size.
Study: NCT00492297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)
Description: Dacarbazine 1000 mg/m\^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
Study: NCT00888654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-Dim
Description: B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prosatectomy
Study: NCT04081688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 MG in 20 ML Injection
Description: Given IV every 3 weeks (cycle is 21 days)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT between cycle 1 and cycle 2 (each cycle is 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlilumab 3 mg/kg
Description: Given IV every 3 weeks (cycle is 21 days)
Study: NCT03287765

Intervention type: DRUG
Intervention: 18F-AV-1451
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study: NCT01524315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B1-ratiopharm
Description: 300 mg Thiaminchloridhydrochlorid, once, intravenous, preoperative

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml normal saline, intravenous, preoperative
Study: NCT00012116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
Study: NCT02891512

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ELF
Description: Very low frequency magnetic fields (ELF) at intensity of 100 mT and a frequency of 1-80 Hz. Protocol (antiedema-antinflammatory): 12 sessions, 3 times a week for 4 consecutive weeks, each session lasted 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELF
Description: Very low frequency magnetic fields (ELF) at intensity of 100 mT and a frequency of 1-80 Hz. Protocol (antiedema-antinflammatory): 12 sessions, 3 times a week for 4 consecutive weeks, each session lasted 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xinepa®
Description: 2 tablets of Xinepa daily (morning and evening) for 1 month.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Xinepa®
Description: 2 tablets of Xinepa placebo daily (morning and evening) for 1 month.